Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Antiparkinsonian

or [[:Category:Catecholamines|Catecholamine]]

Use the filters below to narrow your results.

Agomelatine (1) · Amantadine (1) · Amoxapine (1) · Apomorphine (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Clomipramine (1) · Desipramine (1) · Duloxetine (1) · Entacapone (1) · Epinephrine (adrenaline) (1) · Imipramine (1) · Isocarboxazid (1) · Levodopa (1) · Levomilnacipran (1) · Maprotiline (1) · Milnacipran (1) · Moclobemide (1) · Nefazodone (1) · Opicapone (1) · Phenelzine (1) · Protriptyline (1) · Rasagiline (1) · Reboxetine (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Sertraline (1) · Tianeptine (1) · Tolcapone (1) · Tranylcypromine (1) · Trihexyphenidyl (1) · Trimipramine (1)

None (2) · Akineton (1) · Anafranil (1) · Apokyn (1) · Artane (1) · Aurorix (1) · Azilect (1) · Cogentin (1) · Comtan (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Dostinex (1) · Edronax (1) · Eldepryl (1) · EpiPen, EpiPen Jr, Auvi-Q, Adrenaclick, Symjepi; many generic (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Neupro (1) · Norpramin (1) · Ongentys (1) · Parlodel (1) · Parnate (1) · Savella (1) · Serzone (1) · Sinemet (1) · Stablon (1) · Surmontil (1) · Symmetrel (1) · Tasmar (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Xadago (1) · Zoloft (1)

Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Irreversible non-selective MAO inhibitor (3) · Irreversible selective MAO-B inhibitor (2) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective M1 muscarinic antagonist (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-00000E4A-QINU`"' The narrow safe-bolus window for IV use (sharp risk of arrhythmia, hypertensive emergency, intracerebral hemorrhage) is why anaphylaxis dosing is '''IM, not IV''', outside critical care'"`UNIQ--ref-00000E4B-QINU`"'. (1)

None (34) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000E4C-QINU`"', '"`UNIQ--vote-00000E4D-QINU`"', '"`UNIQ--vote-00000E4E-QINU`"', '"`UNIQ--vote-00000E4F-QINU`"', '"`UNIQ--vote-00000E50-QINU`"', '"`UNIQ--vote-00000E51-QINU`"' (1)

None (34) · 25 mg (1) · Anaphylaxis IM 0.3-0.5 mg (adult) into lateral thigh, repeat q5-15 minutes prn; pediatric 0.01 mg/kg IM (max 0.3 mg, max 0.5 mg in adolescents); cardiac arrest 1 mg IV/IO q3-5 minutes; severe asthma neb 0.1 mg/kg up to 5 mg; never IV bolus for anaphylaxis outside critical care (1)

None (34) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Auto-injectors 0.15 mg (Jr/pediatric), 0.3 mg (adult); 1 mg/mL (1:1,000) ampules for IM/SC use; 0.1 mg/mL (1:10,000) for IV use; 2.25% racemic nebulizer (1)

None (34) · 200 mg/d (1) · Indication-specific; ACLS no fixed cumulative ceiling (1)

None (33) · endotracheal (legacy ACLS (1) · IM (1) · intracardiac (historical only) (1) · IV (1) · nebulized (1) · not preferred) (1) · Oral (2) · SC (less common) (1)

None (33) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · IM: 5-10 minutes; IV: seconds; nebulized: 5-10 minutes (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (33) · 5-15 minutes (1) · Chronic daily dosing (1) · Long (1)

None (33) · ~12 hours (1) · ~2 minutes'"`UNIQ--ref-00000E52-QINU`"' (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (33) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · IM/SC ~100%; oral negligible (extensive first-pass and gut metabolism — hence the no-oral route)'"`UNIQ--ref-00000E53-QINU`"' (1) · ~50% (highly variable) (1)

None (33) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Used in life-threatening obstetric anaphylaxis without hesitation; benefits clearly outweigh.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (33) · Rx-only (1) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1)